A High-Content Screen for the Identification of Plant Extracts With

Total Page:16

File Type:pdf, Size:1020Kb

A High-Content Screen for the Identification of Plant Extracts With pharmaceuticals Article A High-Content Screen for the Identification of Plant Extracts with Insulin Secretion-Modulating Activity Roland Hager 1 , Johannes Pitsch 1,2 , Jakob Kerbl-Knapp 1, Cathrina Neuhauser 1, Nicole Ollinger 2 , Marcus Iken 3, Josef Ranner 4, Verena Mittermeier-Kleßinger 4 , Corinna Dawid 4 , Peter Lanzerstorfer 1,* and Julian Weghuber 1,2,* 1 School of Engineering, University of Applied Sciences Upper Austria, 4600 Wels, Austria; [email protected] (R.H.); [email protected] (J.P.); [email protected] (J.K.-K.); [email protected] (C.N.) 2 FFoQSI—Austrian Competence Center for Feed and Food Quality, 3430 Tulln, Austria; [email protected] 3 PM International AG, 5445 Schengen, Luxembourg; [email protected] 4 Food Chemistry and Molecular Sensory Science, Technical University of Munich, 85354 Freising, Germany; [email protected] (J.R.); [email protected] (V.M.-K.); [email protected] (C.D.) * Correspondence: [email protected] (P.L.); [email protected] (J.W.); Tel.: +43-050-804-44402 (P.L.); +43-050-804-44403 (J.W.) Abstract: Bioactive plant compounds and extracts are of special interest for the development of pharmaceuticals. Here, we describe the screening of more than 1100 aqueous plant extracts and synthetic reference compounds for their ability to stimulate or inhibit insulin secretion. To quantify Citation: Hager, R.; Pitsch, J.; insulin secretion in living MIN6 β cells, an insulin–Gaussia luciferase (Ins-GLuc) biosensor was used. Kerbl-Knapp, J.; Neuhauser, C.; Positive hits included extracts from Quillaja saponaria, Anagallis arvensis, Sapindus mukorossi, Gleditsia Ollinger, N.; Iken, M.; Ranner, J.; sinensis and Albizia julibrissin, which were identified as insulin secretion stimulators, whereas extracts Mittermeier-Kleßinger, V.; Dawid, C.; Acacia catechu Myrtus communis Actaea spicata Vaccinium vitis-idaea Calendula officinalis Lanzerstorfer, P.; et al. A of , , L., and were High-Content Screen for the found to exhibit insulin secretion inhibitory properties. Gas chromatography-mass spectrometry Identification of Plant Extracts with (GC-MS) and liquid chromatography-mass spectrometry (LC-MS) were used to characterize several Insulin Secretion-Modulating Activity. bioactive compounds in the selected plant extracts, and these bioactives were retested for their insulin- Pharmaceuticals 2021, 14, 809. https:// modulating properties. Overall, we identified several plant extracts and some of their bioactive doi.org/10.3390/ph14080809 compounds that may be used to manipulate pancreatic insulin secretion. Academic Editors: Dejan Stojkovi´c Keywords: insulin; luciferase; natural plant extracts; bioactives; diabetes; β cells; screening; GC-MS; and Marina Sokovic LC-MS; Western blotting; natural compounds Received: 20 May 2021 Accepted: 10 August 2021 Published: 17 August 2021 1. Introduction Publisher’s Note: MDPI stays neutral Metabolic diseases are global health problems that are rapidly increasing worldwide. with regard to jurisdictional claims in In this regard, energy metabolism represents a key player that is controlled by insulin published maps and institutional affil- secretion from pancreatic β cells. Glucose-stimulated insulin secretion (GSIS) in these iations. cells is controlled by various factors [1]. When the ambient blood glucose concentration increases, glucose is transported by selective transporters into β cells. Elevated glucose levels induce intracellular energy and metabolic processes with a subsequent increase in the ATP/ADP ratio followed by the closure of ATP-triggered potassium (KATP) channels. Due to the inhibition of K channels, the exit of potassium from cells is blocked, resulting in Copyright: © 2021 by the authors. ATP 2+ Licensee MDPI, Basel, Switzerland. membrane depolarization. Voltage-dependent Ca channels (VDCCs) are thus activated, 2+ 2+ This article is an open access article allowing Ca influx; this increase in cytosolic Ca concentration then initiates GSIS. This distributed under the terms and triggering pathway is followed by a time-dependent increase in insulin secretion [2,3]. conditions of the Creative Commons A proposed simplified network of insulin exocytosis from pancreatic β cells is shown Attribution (CC BY) license (https:// in Figure1A. The intracellular network for the regulation of GSIS is very complex and creativecommons.org/licenses/by/ multifactorial. A large number of factors, including mediators of the autonomous nervous 4.0/). system, hormones and nutrients, must be considered [4,5]. Pharmaceuticals 2021, 14, 809. https://doi.org/10.3390/ph14080809 https://www.mdpi.com/journal/pharmaceuticals Pharmaceuticals 2021, 14, 809 2 of 23 Pharmaceuticals 2021, 14, 809 2 of 23 FigureFigure 1. Schematic 1. Schematic overview overview of the of GSIS the pathwayGSIS pathway from pancreatic from pancreaticβ cells that β cells produce that andproduce secrete and secrete insulininsulin in response in response to changes to changes in ambient in ambient blood glucoseblood glucose concentrations. concentrations. Glucose entersGlucose the enters cell via the cell via thethe glucose glucose transporter transporter GLUT2 GLUT2 and is and metabolized is metabolized to pyruvate to pyruvate and ATP. Theand generatedATP. The ATP generated binds to ATP binds to and closes ATP-dependent potassium channels (KATP channels). Due to channel closure, potas- and closes ATP-dependent potassium channels (KATP channels). Due to channel closure, potassium exitsium is blocked, exit is resultingblocked, inresulting depolarization in depolarization of the cell membrane. of the cell membrane. Voltage-gated Voltage calcium-gated channels calcium chan- arenels thus ar triggered,e thus triggered, and an influx and of an calcium influx occurs.of calcium The elevatedoccurs. cytoplasmicThe elevated calcium cytoplasmic concentration calcium concen- triggerstration the triggers release of the insulin release and of C-peptide insulin inand equimolar C-peptide amounts in equimolar (A). Insulin amounts secretion (A depending). Insulin secretion depending on different glucose concentrations in MIN6 β cells and in response to 35 mM KCl. Fold on different glucose concentrations in MIN6 β cells and in response to 35 mM KCl. Fold changes changes in the secreted luciferase activity expressing Ins-GLuc normalized to the activity of 0 mM in the secreted luciferase activity expressing Ins-GLuc normalized to the activity of 0 mM glucose glucose and expressed as fold change ± SEM. Data are the average of at least three independent and expressed as fold change ± SEM. Data are the average of at least three independent experiments experiments with a minimum of 17 replicates in total (B). Schematic overview of the insulin secre- with a minimum of 17 replicates in total (B). Schematic overview of the insulin secretion stimulation tion stimulation and suppression assay (C). MIN6 β cells were cultured in flasks or dishes, tryp- and suppression assay (C). MIN6 β cells were cultured in flasks or dishes, trypsinized, counted sinized, counted and diluted in cell culture media (1). Cells (200 µL) were aliquoted into wells of a and diluted in cell culture media (1). Cells (200 µL) were aliquoted into wells of a 96-well plate 96-well plate and cultured before washing and starving in KRPH buffer and incubation with plant and cultured before washing and starving in KRPH buffer and incubation with plant extracts (2). extracts (2). Fifty microliters of supernatant were removed, pipetted into a white 96-well plate and Fiftymixed microliters with working of supernatant solution were (3). removed, Luminescence pipetted was into measured a white 96-well immediately plate and after mixed pipetting with (4). To workingtest the solution suppression (3). Luminescence of insulin secretion was measured of the immediatelyplant extracts, after 10 pipetting mM glucose (4). Towas test added the (5) after suppressionincubation of insulinwith different secretion plant of the extracts plant extracts, (2). Assay 10 mM preparation glucose was and added measurements (5) after incubation (6, 7) were per- withformed different as described plant extracts previously (2). Assay (3, preparation4). and measurements (6, 7) were performed as described previously (3, 4). Currently,Currently, there there are numerous are numerous antidiabetic antidiabetic agents agents available available for the treatmentfor the treatment of dia- of dia- betesbetes mellitus mellitus (DM), (DM), which which target target different different receptors receptors [6]. The [6] most. The important most important classes of classes of antidiabeticantidiabetic oral oral medicines medicines include include biguanides, biguanides, such assuch metformin, as metformin, sulfonylureas, sulfonylureas, megli- megliti- tinide,nide, thiazolidinedione, thiazolidinedione, dipeptidyl dipeptidyl peptidase peptidase 4 inhibitors, 4 inhibitors, sodium sodium glucose cotransporterglucose cotransporter (SGLT2)(SGLT2) inhibitors inhibitors and αand-glucosidase α-glucosidase inhibitors inhibitors [7,8]. Sulfonylureas [7,8]. Sulfonylureas increase increase insulin se- insulin se- cretioncretion by blockingby blocking KATP KATPchannels channels and and therefore therefore lower lower blood blood glucose glucose levels. levels. They areThey are di- dividedvided into into first-generation first-generation agents, agents, such such as tolbutamide, as tolbutamide, chlorpropamide, chlorpropamide, acetohexamide, acetohexamide,
Recommended publications
  • (Trulicity) Pen and the Semaglutide (Ozempic) Pen
    Protocol H9X-MC-B021(b) Crossover Study Comparing Dulaglutide (Trulicity) Pen and the Semaglutide (Ozempic) Pen NCT03724981 Approval Date: 30-Nov-2018 H9X-MC-B021(b) Clinical Protocol Page 1 Protocol H9X-MC-B021(b): Crossover Study Comparing the Dulaglutide (Trulicity) Pen and the Semaglutide (Ozempic) Pen Confidential Information The information contained in this document is confidential and is intended for the use of clinical investigators. It is the property of Eli Lilly and Company or its subsidiaries and should not be copied by or distributed to persons not involved in the clinical investigation of dulaglutide (LY2189265), unless such persons are bound by a confidentiality agreement with Eli Lilly and Company or its subsidiaries. Note to Regulatory Authorities: This document may contain protected personal data and/or commercially confidential information exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public release. In the United States, this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not be reproduced or otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries. Dulaglutide (LY2189265) Eli Lilly and Company Indianapolis, Indiana USA 46285 Protocol Electronically Signed and Approved by Lilly on 07 Aug 2018 Amendment (a) Electronically Signed and Approved by Lilly on 11 Sep 2018 Amendment (b) Electronically Signed and Approved by Lilly on date below Approval Date: 30-Nov-2018 GMT LY2189265 H9X-MC-B021(b) Clinical Protocol Page 2 Table of Contents Section Page Protocol H9X-MC-B021(b): Crossover Study Comparing the Dulaglutide (Trulicity) Pen and the Semaglutide (Ozempic) Pen ............................................................1 Table of Contents........................................................................................................................2 1.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Sulfonylurea Review
    Human Journals Review Article February 2018 Vol.:11, Issue:3 © All rights are reserved by Farah Yousef et al. Sulfonylurea Review Keywords: Type II diabetes, Sulfonylurea, Glimipiride, Glybu- ride, Structure Activity Relationship. ABSTRACT Farah Yousef*1, Oussama Mansour2, Jehad Herbali3 Diabetes Mellitus is a chronic disease represented with high 1 Ph.D. candidate in pharmaceutical sciences, Damas- glucose blood levels. Although sulfonylurea compounds are the cus University, Damascus, Syria. second preferred drug to treat Type II Diabetes (TYIID), they are still the most used agents due to their lower cost and as a 2 Assistant Professor in pharmaceutical chimestry, Ti- mono-dosing. Literature divides these compounds according to st nd rd shreen University, Lattakia, Syria their discovery into 1 , 2 , 3 generations. However, only six sulfonylurea compounds are now available for use in the United 3 Assistant Professor in pharmaceutical chimestry, Da- States: Chlorpropamide, Glimepiride, Glipizide, Glyburide, mascus University, Damascus, Syria. Tolazamide, and Tolbutamide. They function by increasing Submission: 24 January 2018 insulin secretion from pancreatic beta cells. Their main active site is ATP sensitive potassium ion channels; Kir 6.2\SUR1; Accepted: 29 January 2018 Published: 28 February 2018 Potassium Inward Rectifier ion channel 6.2\ Sulfonylurea re- ceptor 1. They are sulfonamide derivatives. However, research- ers have declared that sulfonylurea moiety is not the only one responsible for this group efficacy. It has been known that sud- den and acute hypoglycemia incidences and weight gain are the www.ijppr.humanjournals.com two most common adverse effects TYIID the patient might face during treatment with sulfonylurea agents. This review indi- cates the historical development of sulfonylurea and the differ- ences among this group members.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Pharmacoepidemiological Study Report Synopsis ER-9489 A
    DAHLIA Report synopsis ER-9489 Version 1.0 14 November 2017 Pharmacoepidemiological study report synopsis ER-9489 A retrospective nationwide cohort study to investigate the treatment of type 2 diAbetic pAtients in Finland - DAHLIA Authors: Solomon Christopher, Anna Lundin, Minna Vehkala, Fabian Hoti Study ID: ER-9489 Sponsor: AstraZeneca Nordic Baltic Report version: 1.0 Report date: 14 November 2017 EPID ReseArch CONFIDENTIAL DAHLIA Report synopsis ER-9489 Version 1.0 14 November 2017 Study Information Title A retrospective nationwide cohort study to investigate the treatment of type 2 diabetic patients in Finland – DAHLIA Study ID ER-9489 Report synopsis version 1.0 Report synopsis date 14 November 2017 EU PAS register number ENCEPP/SDPP/8202 Sponsor AstraZeneca Nordic Baltic SE-151 85 Södertälje, Sweden Sponsor contact person Susanna Jerström, Medical Evidence Manager Medical Nordic-Baltic SE-151 85 Södertälje, Sweden Active substance ATC codes A10 (Drugs used in diabetes) Medicinal product The folloWing AstraZeneca products are available on the Finnish market: Bydureon (exenatide A10BX04), Byetta (exenatide A10BX04), Forxiga (dapagliflozin A10BX09), Komboglyze (metformine and saxagliptin A10BD10), Onglyza (saxagliptin A10BH03), Xigduo (dapagliflozin and metformin A10BD15) Country of study Finland Authors of the report Solomon Christopher, Anna Lundin, Minna Vehkala, Fabian Hoti synopsis EPID ReseArch Page 2 of 43 DAHLIA Report synopsis ER-9489 Version 1.0 14 November 2017 Table of contents 1 Study report summary (Abstract) ...........................................................................................
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • The Use of Sequential Pattern Mining to Predict Next Prescribed Medications ⇑ Aileen P
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Elsevier - Publisher Connector Journal of Biomedical Informatics 53 (2015) 73–80 Contents lists available at ScienceDirect Journal of Biomedical Informatics journal homepage: www.elsevier.com/locate/yjbin The use of sequential pattern mining to predict next prescribed medications ⇑ Aileen P. Wright a, , Adam T. Wright b, Allison B. McCoy c, Dean F. Sittig d a Yale School of Medicine, New Haven, CT, United States b Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States c Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, United States d The University of Texas School of Biomedical Informatics at Houston and the UT-Memorial Hermann Center for Healthcare Quality & Safety, Houston, TX, United States article info abstract Article history: Background: Therapy for certain medical conditions occurs in a stepwise fashion, where one medication Received 13 March 2014 is recommended as initial therapy and other medications follow. Sequential pattern mining is a data Accepted 8 September 2014 mining technique used to identify patterns of ordered events. Available online 16 September 2014 Objective: To determine whether sequential pattern mining is effective for identifying temporal relation- ships between medications and accurately predicting the next medication likely to be prescribed for a Keywords: patient. Sequential pattern mining Design: We obtained claims data from Blue Cross Blue Shield of Texas for patients prescribed at least one Data mining diabetes medication between 2008 and 2011, and divided these into a training set (90% of patients) and Knowledge base Clinical decision support test set (10% of patients).
    [Show full text]
  • Assessment of Cardiovascular Effects of Non-Insulin Blood-Glucose-Lowering Agents Nelly Herrera Comoglio
    Assessment of cardiovascular effects of non-insulin blood-glucose-lowering agents Nelly Herrera Comoglio To cite this version: Nelly Herrera Comoglio. Assessment of cardiovascular effects of non-insulin blood-glucose-lowering agents. Human health and pathology. Université de Bordeaux, 2019. English. NNT : 2019BORD0355. tel-02969556 HAL Id: tel-02969556 https://tel.archives-ouvertes.fr/tel-02969556 Submitted on 16 Oct 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. THÈSE PRÉSENTÉE POUR OBTENIR LE GRADE DE DOCTEUR DE L’UNIVERSITÉ DE BORDEAUX ÉCOLE DOCTORALE SPÉCIALITÉ PHARMACOÉPIDEMIOLOGIE Option Pharmaco-épidémiologie, pharmaco-vigilance Par Nelly Raquel HERRERA COMOGLIO TITRE : ÉVÉNEMENTS CARDIOVASCULAIRES MAJEURS ET MORTALITÉ EN PATIENTS TRAITÉS AVEC DES HYPOGLYCÉMIANTS NON INSULINIQUES Étude de cohortes basée sur une population de Catalogne, Espagne Sous la direction de : Xavier VIDAL GUITART Soutenue le 17 Décembre 2019 Membres du jury : Mme. AGUSTI ESCASANY, Antonia Prof. Fundacio Institut Catala de Farmacologia Président, rapporteur Mme. BOSCH Montserrat Prof. Associée Fundacio Institut Catala de Farmacologia Examinateur M. SALVO, Francesco Prof. Université de Bordeaux Examinateur Titre : ÉVÉNEMENTS CARDIOVASCULAIRES MAJEURS ET MORTALITÉ EN PATIENTS TRAITÉS AVEC DES HYPOGLYCÉMIANTS NON INSULINIQUES Étude de cohortes basée sur une population de Catalogne, Espagne Résumé : Le diabète mellitus Type 2 (DMT2) est une maladie chronique et progressive causée par multiples facteurs.
    [Show full text]
  • A Molecular Approach to the Modulation of Pharmacokinetics: Modification of Metabolic Conversion by Molecular Manipulation
    A MOLECULAR APPROACH TO THE MODULATION OF PHARMACOKINETICS: MODIFICATION OF METABOLIC CONVERSION BY MOLECULAR MANIPULATION E. J. ARIENS Farinacologisch Laboratoriu,n, Universiteit Nijinegen, Netherlands INTRODUCTION In pharmacology the interest in the question: "what are the effects of drugs?" has shifted more and more to the basic question: "how do drugs act?" Whatever the pharmacodynamic effect of a drug may be, it can only be due to an interaction between the molecules of the drug and the molecules constituting the biological object. Taking into account the usually small doses of drugs required to obtain responses, even in large animals, only an ex- tremely small fraction of the molecules in the biological object can be primarily involved in the drug action. An insight in the various types of molecular interactions in which the drug molecules take part in the body are an essential requisite in the rational approach to the development of new drugs. From a functional point of view the interactions of the drug molecules with all kinds of molecules in the biological object can be differentiated in different types, especially according to the molecular sites of action and the consequences of the interaction: 1. Those molecular sites of interaction which are directly and essentially involved in the induction of the effect. They usually are indicated as the sites of action for the drug. They are characteristic for the type of response, e.g. cholinergic, curariform, convulsant, antihistaminic, etc. 2. The molecular sites of interaction which are neither directly nor essentially involved in the induction of the effect, but which mainly influence the distribution of the drug over the various compartments.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • 2020 Diabetes Guideline Data Supplement
    Data Supplement Appendix A: Search strategies Table S1. Search strategies for systematic review topics Search dates – RCTs October 2018, Systematic reviews October 2018, Observational studies February 2019; Updated February 2020 Guideline chapter Comprehensive care in diabetes and CKD Systematic review topic RAS inhibitors in patients with diabetes and CKD Search strategy - 1. MeSH descriptor: [Angiotensin-Converting Enzyme Inhibitors] explode all trees CENTRAL 2. MeSH descriptor: [Angiotensin Receptor Antagonists] explode all trees 3. losartan:ti,ab,kw (Word variations have been searched) 4. irbesartan:ti,ab,kw (Word variations have been searched) 5. candesartan:ti,ab,kw (Word variations have been searched) 6. eprosartan:ti,ab,kw (Word variations have been searched) 7. valsartan:ti,ab,kw (Word variations have been searched) 8. olmesartan:ti,ab,kw (Word variations have been searched) 9. telmisartan:ti,ab,kw (Word variations have been searched) 10. captopril:ti,ab,kw (Word variations have been searched) 11. enalapril:ti,ab,kw (Word variations have been searched) 12. fosinopril:ti,ab,kw (Word variations have been searched) 13. lisinopril:ti,ab,kw (Word variations have been searched) 14. perindopril:ti,ab,kw (Word variations have been searched) 15. MeSH descriptor: [Diabetic Nephropathies] this term only 16. diabetic nephropath*:ti,ab,kw (Word variations have been searched) 17. diabetic kidney* or diabetic renal*:ti,ab,kw (Word variations have been searched) 18. MeSH descriptor: [Albuminuria] this term only 19. MeSH descriptor: [Proteinuria] this term only 20. proteinuria or albuminuria or microalbuminuria or macroalbuminuria:ti,ab,kw (Word variations have been searched) Search strategy - 1. exp Angiotensin-Converting Enzyme Inhibitors/ MEDLINE 2.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]